Canagliflozin increased urinary glucose excretion in a dose-dependent manner and produced statistically significant reductions in body weight compared with placebo ( least squares mean percent changes from baseline of -2.2 % , -2.9 % , -2.7 % , and -1.3 % with canagliflozin 50 , 100 , and 300 mg and placebo ; P < 0.05 for all comparisons ) .